{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:06:44Z","timestamp":1778569604215,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008791","name":"Bayer CropScience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10147-019-01589-6","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T18:03:53Z","timestamp":1576001033000},"page":"720-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study"],"prefix":"10.1007","volume":"25","author":[{"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motonobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nagamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kikukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Krissel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14656566.2015.995090","volume":"16","author":"T Zhang","year":"2015","unstructured":"Zhang T, Zhu J, George DJ et al (2015) Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 16:473\u2013485","journal-title":"Expert Opin Pharmacother"},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.4155\/fmc.16.12","volume":"8","author":"M Zuo","year":"2016","unstructured":"Zuo M, Xu X, Li T et al (2016) Progress in the mechanism and drug development of castration-resistant prostate cancer. Future Med Chem 8:765\u2013788","journal-title":"Future Med Chem"},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","volume":"23","author":"MI Suominen","year":"2017","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP et al (2017) Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res 23:4335\u20134346","journal-title":"Clin Cancer Res"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223","journal-title":"N Engl J Med"},{"key":"1589_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"S Nilsson","year":"2016","unstructured":"Nilsson S, Cislo P, Sartor O et al (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 27:868\u2013874","journal-title":"Ann Oncol"},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","volume":"73","author":"CC Parker","year":"2018","unstructured":"Parker CC, Coleman RE, Sartor O et al (2018) Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial. Eur Urol 73:427\u2013435","journal-title":"Eur Urol"},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","volume":"17","author":"F Saad","year":"2016","unstructured":"Saad F, Carles J, Gillessen S et al (2016) Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 17:1306\u20131316","journal-title":"Lancet Oncol"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2017-0413","volume":"23","author":"O Sartor","year":"2018","unstructured":"Sartor O, Vogelzang NJ, Sweeney C et al (2018) Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an Expanded Access Program. Oncologist 23:193\u2013202","journal-title":"Oncologist"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408\u2013419","journal-title":"Lancet Oncol"},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10147-017-1130-1","volume":"22","author":"H Uemura","year":"2017","unstructured":"Uemura H, Uemura H, Matsubara N et al (2017) Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. Int J Clin Oncol 22:954\u2013963","journal-title":"Int J Clin Oncol"},{"key":"1589_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10147-017-1176-0","volume":"23","author":"N Matsubara","year":"2018","unstructured":"Matsubara N, Nagamori S, Wakumoto Y et al (2018) Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Int J Clin Oncol 23:173\u2013180","journal-title":"Int J Clin Oncol"},{"key":"1589_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12149-018-1317-1","volume":"33","author":"M Hosono","year":"2019","unstructured":"Hosono M, Ikebuchi H, Nakamura Y et al (2019) Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation. Ann Nucl Med 33:211\u2013221","journal-title":"Ann Nucl Med"},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1589_CR14","first-page":"11459","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:11459\u201311482","journal-title":"J Clin Oncol"},{"key":"1589_CR15","unstructured":"By Enzyme\/Reagent Special Committee of Japanese Society of Clinical Chemistry, Reference material for request of public comment [Regarding the relationship between current and revised JSCC standard methods and IFCC standard measurement method], in Japanese, [cited 2019 Aug 1]. http:\/\/jscc-jp.gr.jp\/home\/wp-content\/uploads\/2018\/10\/ALP-Public-Comment_HP.pdf"},{"key":"1589_CR16","first-page":"187","volume":"10","author":"H Akaza","year":"2013","unstructured":"Akaza H (2013) Asian trends in primary androgen depletion therapy on prostate cancer. Cancer Biol Med 10:187\u2013191","journal-title":"Cancer Biol Med"},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"e0195789","DOI":"10.1371\/journal.pone.0195789","volume":"13","author":"S Cheung","year":"2018","unstructured":"Cheung S, Hamuro Y, Mahlich J et al (2018) Treatment pathways of Japanese prostate cancer patients\u2014a retrospective transition analysis with administrative data. PLoS One 13:e0195789","journal-title":"PLoS One"},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/cas.12496","volume":"105","author":"N Matsubara","year":"2014","unstructured":"Matsubara N, Uemura H, Fukui I et al (2014) Phase-1 study of abiraterone acetate in chemotherapy-na\u00efve Japanese patients with castration-resistant prostate cancer. Cancer Sci 105:1313\u20131320","journal-title":"Cancer Sci"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jjco\/hyu149","volume":"44","author":"N Matsubara","year":"2014","unstructured":"Matsubara N, Uemura H, Satoh T et al (2014) A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol 44:1216\u20131226","journal-title":"Jpn J Clin Oncol"},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jjco\/hyy129","volume":"48","author":"S Fukasawa","year":"2018","unstructured":"Fukasawa S, Suzuki H, Kawaguchi K et al (2018) Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-na\u00efve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn J Clin Oncol 48:1012\u20131021","journal-title":"Jpn J Clin Oncol"},{"key":"1589_CR21","unstructured":"Mottet N, van den Bergh RCN, Briers E et al (2019) European association of urology (EAU) prostate cancer guidelines. https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed 19 Nov 2019"},{"key":"1589_CR22","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. Prostate Cancer (version 4.2019\u2014August 19, 2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 19 Nov 2019"},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","volume":"200","author":"WT Lowrance","year":"2018","unstructured":"Lowrance WT, Murad MH, Oh WK et al (2018) Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol 200:1264\u20131272","journal-title":"J Urol"},{"key":"1589_CR24","doi-asserted-by":"crossref","unstructured":"Kakehi Y, Sugimoto M, Taoka R et al (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 24:648\u2013666","DOI":"10.1111\/iju.13380"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01589-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:55:22Z","timestamp":1607478922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01589-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors disclose the following conflicts of interest: Nobuaki Matsubara has received research funding from Bayer. Go Kimura has received honoraria from Bayer. Hiroji Uemura has received research funding from Astellas, honoraria from Bayer, Janssen, Astellas, Takeda and Astra Zeneca, and received travel expenses from Janssen, Bayer, Astellas, Takeda and Astra Zeneca. Hirotsugu Uemura has received research funding from Astra Zeneca, Sanofi, Janssen, Takeda and Astellas, honoraria from Bayer, Astra Zeneca, Takeda, Sanofi, Janssen and Astellas, and has acted as an advisor to Sanofi, Janssen, and Bayer. Atsushi Mizokami has received honoraria from Bayer. Seigo Kinuya has received honoraria from Bayer. Heiko Krissel and Jonathan Siegel own stocks of Bayer AG, and are employees of Bayer AG and Bayer HealthCare Pharmaceuticals, respectively. All remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}